髓鞘少突胶质细胞糖蛋白抗体相关疾病的免疫治疗进展

Progress in immunotherapy of myelin oligodendrocyte glycoprotein-IgG associated disorders

髓鞘少突胶质细胞糖蛋白抗体相关疾病(myelin oligodendrocyte glycoprotein-IgG associated disorders,MOGAD)是一种新近认识到的免疫介导的中枢神经系统炎性脱髓鞘疾病。该病可表现为单相或复发病程,反复发作可遗留严重神经功能障碍,控制急性发作和预防复发是治疗的重点,手段包括激素、免疫抑制剂和生物制剂等。文中将对MOGAD的免疫治疗进展做一综述。

Myelin oligodendrocyte glycoprotein-IgG associated disorders(MOGAD)are newly recognized immune-mediated inflammatory demyelinating diseases of the central nervous system.The diseases can be manifested as a single-phase or recurrent course,recurrent episodes of which can leave serious neurological dysfunction,and control of acute attacks and prevention of recurrence is the focus of treatment,including steroids,immunosuppressants and biological agents.This article will review the progress of immunotherapy for MOGAD.